Stockreport

MaxCyte Signs Strategic Platform License with TG Therapeutics to Advance its Autoimmune Cell Therapeutics Programs

MaxCyte, Inc.  (MXCT) 
PDF ROCKVILLE, Md., Feb. 12, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform tec [Read more]